Supplement · CFMG–Wellpath California · Published 25 September 2026 · Record current through 25 September 2026 · Last updated 25 September 2026

California’s Corporate-Practice Enforcement Record, 2021–2026

How the Attorney General and the Medical Board are testing the friendly-PC / MSO model. A public-record sweep from September 2021 through 25 September 2026, separating Attorney General actions, Medical Board and Osteopathic Board enforcement, amicus briefs and court decisions, and the SB 351 / AB 3129 / AB 1415 legislative shift — then mapping each control indicator to what the CFMG–Wellpath record does and does not show.

Executive finding

California's public enforcement record has changed materially during 2026. The state is no longer speaking about the corporate-practice-of-medicine doctrine only through general Medical Board guidance or physician discipline. The Attorney General has now placed the friendly-professional-corporation / management-services-organization architecture itself at the center of two highly visible matters: the pending Art Center Holdings appeal and the Carbon Health enforcement action. In each, the state focuses not merely on whether a professional corporation is nominally physician-owned, but on whether an unlicensed management organization possesses contractual or practical rights that amount to effective control of the professional corporation.

The most important control questions appearing across the 2021–2026 record are remarkably consistent:

1. Who can replace the physician shareholder or owner?
2. Can the physician owner terminate or replace the MSO without losing the practice or being forced to transfer the shares?
3. Who controls or materially directs hiring, firing, compensation, staffing and supervision of licensed professionals?
4. Who sets patient volume, physician workload or hours?
5. Who controls payer-contract parameters and insurance negotiations?
6. Who controls coding and billing decisions?
7. Who owns or determines the content and control of patient medical records?
8. Who selects or approves medical equipment and supplies?
9. Who controls professional advertising and represents itself to the public as the provider?
10. Who possesses the financing, security, option, succession, assignment or termination rights that can make nominal physician ownership economically non-independent?
11. Who has the last word when the physician corporation and the MSO disagree?
12. Can the physician corporation actually leave the MSO and continue operating as a viable physician-controlled practice?

This is highly relevant to the CFMG–Wellpath investigation, but it is not a finding that the CFMG–Wellpath relationship violates California law. The correct use of the California enforcement record is to build a disciplined comparison matrix: state-recognized control indicator → CFMG/Wellpath evidence → evidentiary status → missing document needed to close the issue.

The September 2026 Fresno Amendment XIII record now makes that comparison more important. Fresno County continues to identify California Forensic Medical Group, Incorporated as the formal contracting counterparty, while the same County record describes Wellpath as the actor that will provide and coordinate the new CalAIM services, collaborate with WestCare and managed-care plans, ensure that “its staff” are credentialed and trained for billable documentation, and use Medusind, Inc. as Wellpath's subcontracted billing vendor. The record is strong evidence of a layered PC–MSO operating system. It is not proof that Wellpath owns CFMG, employs every worker described as “its staff,” or exercises physician-reserved clinical authority.

I. Scope and evidentiary method

This supplement covers the five-year period from approximately 25 September 2021 through 25 September 2026, while using older authority only where necessary to explain the doctrine that the later enforcement actions apply. The sweep prioritizes official California Department of Justice materials, Medical Board of California disciplinary summaries and guidance, Osteopathic Medical Board materials, California statutes and state-agency implementation documents, published court decisions, federal dockets, and clearly identified amicus filings.

The phrase “all actions” must be used carefully. Medical Board investigations can remain confidential; older disciplinary records are not indexed uniformly; and a public search cannot prove that no unindexed accusation, investigation, settlement or referral exists. This document is therefore an exhaustive-oriented public-record inventory, not a representation that every confidential or poorly indexed enforcement matter has been captured.

Each matter is classified as one of the following:

• Adjudicated discipline / final administrative action — a Medical Board decision, reprimand, surrender, revocation or probation order.
• Government allegation / filed enforcement matter — allegations in a government complaint that have not been adjudicated on the merits.
• Proposed or court-approval-dependent settlement — negotiated relief that should not be described as an entered final judgment unless the docket establishes entry.
• Government amicus position — a legal interpretation urged by the Attorney General but not itself a binding appellate holding.
• Private litigation / pleading-stage judicial ruling — useful evidence of how courts analyze allegations, but not a state enforcement finding.
• Regulatory guidance / legislative analysis — authoritative evidence of the regulator's interpretation and policy position, but not an adjudication against a particular entity.

II. The legal baseline before SB 351

California's CPOM framework did not begin with SB 351. Business and Professions Code sections 2052 and 2400, the Moscone-Knox Professional Corporation Act, the Professional Corporations Law, Medical Board guidance, and decades of case law already restricted unlicensed persons and artificial entities from practicing medicine or controlling physician professional judgment.

The Medical Board's current practice guidance identifies two related categories of physician-reserved authority.

First are clinical decisions: diagnostic testing, referrals and consultations, ultimate responsibility for patient care and treatment options, and physician workload or hours. Second are business or management decisions that can become control over the medical practice: control of medical records, selection and hiring or firing of licensed personnel based on clinical competency, payer-contract parameters, clinical competency terms in professional relationships, coding and billing, and selection of medical equipment and supplies. An MSO may provide administrative assistance and consultation, but the physician must retain the ultimate responsibility or approval over nondelegable decisions.

That distinction is central to the CFMG–Wellpath investigation. It means the legal question cannot be answered merely by showing that Wellpath performs extensive administrative work. Nor can it be answered merely by pointing to contractual language saying CFMG retains professional authority. The investigation must identify who actually holds the decisive right and who actually exercises it.

Primary source: Medical Board of California, Practice Information — Corporate Practice of Medicine

III. SB 351: codification, expansion of enforcement tools, and a critical limitation

SB 351, Chapter 409 of the Statutes of 2025, added Health and Safety Code Division 1.7 and became effective 1 January 2026. Section 1191 prohibits a private-equity group or hedge fund involved with a California physician or dental practice from interfering with professional judgment or exercising specified forms of control. The statute specifically identifies diagnostic decisions, referrals, ultimate patient care, patient volume and physician work hours, medical records, clinical hiring and firing, payer-contract parameters, professional contracting based on clinical competency, coding and billing, and medical equipment and supplies.

The statute also attacks certain contractual mechanisms. Agreements that enable the prohibited control are void and unenforceable to that extent. Management-related agreements covered by the statute cannot use specified noncompete or nondisparagement provisions to prevent clinicians from leaving or speaking about quality, ethics or revenue-increasing strategies. The Attorney General is expressly authorized to seek injunctive and other equitable relief and to recover fees and costs.

Two limitations are essential for the Wellpath analysis.

First, section 1191 directly targets private-equity groups and hedge funds, including controlled entities. A historical connection between a healthcare company and private equity does not automatically establish that every present-day post-bankruptcy entity satisfies the statute's definitions. The current ownership and control of the relevant Wellpath/MSO entities must be proven before SB 351 is applied directly.

Second, section 1191(g) expressly says that it does not narrow, abrogate or lower the preexisting California CPOM bar. Therefore, even where SB 351's private-equity/hedge-fund definitions are not satisfied, the older Business and Professions Code, Corporations Code and common-law CPOM framework remains relevant.

This makes SB 351 a powerful analytical overlay, but it should not be retroactively treated as the source of liability for conduct predating 1 January 2026.

Primary/statutory sources:

• California Health & Safety Code §1191
• Osteopathic Medical Board of California, 2026 policy alert summarizing SB 351

IV. California Attorney General / DOJ actions: the modern friendly-PC enforcement record

A. Art Center Holdings, Inc. v. WCE CA Art, LLC — Attorney General amicus, March–April 2026

The Attorney General's Art Center filing is one of the most important California CPOM documents of the last five years because it addresses the contractual architecture of a friendly-PC/MSO relationship rather than only a discrete clinical act.

The appeal, pending in the California Second District Court of Appeal, arose from a dispute between a physician owner and a private-equity-backed MSO. On 30 March 2026 the Attorney General filed an amicus brief supporting neither party but defending the trial court's CPOM holding. The Attorney General publicly announced the filing on 1 April.

The state's two most important propositions are:

• if an unlicensed corporation possesses the contractual right to replace the physician owner with a physician of the corporation's choosing, the corporation can effectively own and control the practice; and
• if the physician owner cannot replace the MSO without risking loss of ownership of the practice, the MSO can possess impermissible or undue control.

The brief examines continuity agreements, assignable options, stock-transfer arrangements and similar contractual devices by which the physician shareholder may be nominally independent while the management company preserves practical continuity over ownership. The Attorney General also relies on Medical Board control factors concerning staffing, compensation and professional employment.

The qualification is crucial: the Attorney General's brief is advocacy, not a final appellate holding. The appeal remained pending in the public record reviewed for this supplement. The California Medical Association separately filed an amicus brief urging a contextual and fact-dependent analysis rather than treating every friendly-PC mechanism categorically. That disagreement should be preserved on the website because it demonstrates that the precise boundary remains litigated.

Sources:

• California DOJ announcement
• California Attorney General amicus brief
• California Medical Association announcement

CFMG/Wellpath relevance

Art Center makes the missing CFMG ownership and succession instruments substantially more important. The CFMG investigation already has a management agreement and a 2019 assignment into Wellpath LLC. What remains missing is the current stock-transfer, succession, continuity, replacement, option or ownership-preservation instrument, if any. The correct investigative question is not “does CFMG have an MSO?” It plainly does. The question is whether any agreement gives the management side the legal or practical ability to determine who owns the professional corporation or makes terminating the manager economically equivalent to forfeiting the practice.

No public record located in this sweep answers that question for CFMG.

B. People v. Carbon Health Technologies — June 2026 DOJ complaint and announced settlement

Carbon Health is the strongest direct California DOJ enforcement action identified in this five-year sweep involving a modern friendly professional corporation/MSO model.

On 26 June 2026, Attorney General Bonta announced a settlement with Carbon Health Technologies, affiliated medical groups and co-founder Eren Bali. DOJ's complaint alleges that the unlicensed management company effectively owned and controlled the physician practices through a network of contractual rights. The complaint describes management authority over advertising, billing, finances, records, equipment, professional staffing and compensation; consent rights over significant assets, debt and contracts; security interests in physician shares; and succession or option provisions that could cause ownership to move to a physician selected by the management side.

The announced relief requires restructuring so that a nonmedical management company no longer controls or holds prohibited ownership interests in physician practices, together with changes to advertising, patient contracts and billing. The announcement reports $4.4 million in company penalties and $100,000 against Bali.

Procedural status must be stated accurately. The Attorney General's own announcement says the settlement is subject to court approval, and the publicly hosted judgment is captioned [PROPOSED] FINAL JUDGMENT AND PERMANENT INJUNCTION. This sweep did not locate a later public entry conclusively demonstrating that the proposed judgment had been entered. Therefore the site should describe the record as a filed complaint plus announced, court-approval-dependent settlement unless an entered judgment is subsequently located.

Carbon is particularly valuable because it shows that California's control analysis is not confined to direct orders about diagnosis. DOJ treats ownership succession, professional staffing, payer negotiations, billing, equipment, advertising, records and financing arrangements as parts of the same control inquiry.

Sources:

• California DOJ announcement
• Filed complaint
• Proposed judgment

CFMG/Wellpath relevance

Carbon supplies a concrete document-request roadmap for CFMG. The most important CFMG-specific records become: share/security agreements, stock-transfer and option documents, termination rights, exclusive-management clauses, professional staffing approvals, compensation authority, payer contracting, coding and billing authority, EHR/records control, equipment procurement, financing and intercompany-credit arrangements.

The Fresno Amendment XIII evidence concerning Medusind should be treated in this framework. A billing vendor performing audit and quality assurance does not itself establish unlawful control. The unanswered question is who has final authority over coding, billing corrections, claim submission and escalation, and whether the professional corporation retains the ultimate approval required by California law.

C. Aspen Dental — May 2026 corporate-practice-of-dentistry analogue

The Attorney General's May 2026 Aspen Dental settlement is a dentistry case, not a medical CPOM case, but it is a useful parallel because California applies a closely related professional-independence principle to dentistry.

DOJ alleged that Aspen Dental Management, a private-equity-owned dental support organization, exceeded an administrative role by selecting, purchasing, staffing and advertising offices and otherwise directing ownership and management. The announced settlement was also described as subject to court approval and included $2 million in penalties and $300,000 in restitution.

The injunctive themes closely parallel Art Center and Carbon: the support organization may not choose replacement professional owners, make termination of the support company functionally cost the professional owner the practice, own practice property in a manner that creates control, manage professional offices, use revenue/sales/profit-linked management fees in prohibited ways, or use incentives that distort clinical choices.

Because this is dentistry, the website should identify it as parallel professional-corporation enforcement, not medical precedent against CFMG. Its value is that the Attorney General is applying a coherent “professional owner must remain genuinely independent” theory across licensed health professions.

Source: California DOJ, 7 May 2026

D. Orange Twist — DOJ Health Quality Enforcement + Medical Board joint enforcement, 2023–2024

The California DOJ's 2023–2024 Biennial Report describes a pre-SB 351 joint enforcement episode involving the Medical Board and DOJ's Health Quality Enforcement Section. An anonymous complaint alleged that “Orange Twist” was nonphysician-owned while offering medical services. DOJ says the resulting investigations involved med spas in Sephora and other beauty storefronts and physicians functioning as straw “Chief Medical Directors.”

The Medical Board ultimately disciplined Jaime Scott Schwartz, M.D., and Francis R. Palmer III, M.D. The Board summaries state that each matter resolved without admissions while charging aiding and abetting unlicensed practice, violation of the corporate-practice ban, fee splitting, fictitious-name issues and unprofessional conduct. Palmer received a public reprimand and $92,365.75 in cost recovery; Schwartz received a public reprimand and $221,924.75 in cost recovery. DOJ's Biennial Report aggregates cost recovery at $314,290.50 and states that Orange Twist revised its structure to comply with the statutory CPOM framework.

This is important because it demonstrates that before SB 351 California DOJ and the Medical Board were already coordinating investigations of nominal-physician or “straw physician” structures.

Sources:

• California DOJ 2023–2024 Biennial Report
• Medical Board Newsletter, Volume 168

V. Medical Board of California: five-year public disciplinary record

The public disciplinary record is broader than Art Center and Carbon. The Medical Board has repeatedly proceeded against physicians for aiding and abetting unlicensed practice, violating the Moscone-Knox Professional Corporation Act, participating in improperly controlled medical corporations, fee splitting, fictitious-name violations, and allowing nonphysicians to control medical corporations.

The following inventory separates core structural CPOM matters from broader unlicensed-practice matters so that the site does not overstate what each case proves.

Principal Board sources:

• Volume 164 (2022 administrative actions)
• Volume 165
• Volume 166
• Volume 167
• Volume 168
• Volume 169
• Volume 170
• Volume 171
• Volume 172
• Vinh-Linh Ba Nguyen Public Letter of Reprimand

What the disciplinary pattern establishes

The Board's cases show that California treats the physician shareholder and medical director as potential enforcement points when unlicensed persons or improperly constituted business entities practice medicine through them. A physician's name on the professional corporation is not a safe harbor if the structure or operation transfers prohibited authority. At the same time, many stipulated matters contain no admissions, and disciplinary summaries often combine CPOM allegations with patient-care, recordkeeping, fraud or fictitious-name violations. The website should therefore use them as evidence of what conduct the Board charges and regulates, not as proof that every alleged fact was adjudicated after a contested hearing.

2026 Medical Board institutional posture

In May 2026, Medical Board staff's legislative analysis of AB 2311 again described the CPOM doctrine as prohibiting corporations from directly employing professionals or exercising control over licensed professional decision-making in a manner that interferes with independent judgment. The analysis also recalled a 2023 staff recommendation opposing a broad expansion of direct physician employment by healthcare districts because it could weaken longstanding protections against lay influence. This is not an MSO enforcement case, but it confirms that after SB 351 the Board continues to treat CPOM as an active, independent regulatory doctrine rather than a superseded historical rule.

VI. Osteopathic Medical Board of California

The Osteopathic Medical Board's 2026 policy alert identifies SB 351 as a new law effective 1 January 2026 and describes its prohibition on private-equity and hedge-fund interference with physician and dentist professional judgment and specified control functions.

More significantly for interagency posture, the Board's 23 April 2026 public meeting agenda included a presentation specifically titled “Corporate Practice of Medicine” by John Gatschet, Deputy Attorney General, California Attorney General's Office. That is evidence of active regulator/Attorney-General education and coordination after SB 351. It is not itself an enforcement action or a finding against a licensee.

No comparably granular osteopathic disciplinary matter involving a friendly-PC/MSO structure surfaced in the indexed public materials reviewed for this supplement. That should be stated as a search result, not as proof that no such investigation or accusation exists.

Sources:

• OMBC 2026 policy alert
• OMBC 23 April 2026 agenda

VII. Amicus briefs and private litigation that define the boundary

1. AAEM Physician Group v. Envision Healthcare / KKR-related entities

The American Academy of Emergency Medicine Physician Group litigation began in late 2021 and challenged an Envision-related California emergency-medicine structure under Business and Professions Code sections 2052 and 2400. The federal court denied dismissal in 2022. The California Medical Association and the American College of Emergency Physicians filed amicus briefs supporting physician autonomy and the challenge. Envision's later bankruptcy disrupted the case, and AAEM reported a 2024 resolution involving Envision's withdrawal from California emergency-department operations.

The critical limitation is that the case did not produce a final merits judgment declaring the challenged structure unlawful. It remains valuable because it shows that sophisticated physician organizations were already using California CPOM doctrine to attack private-equity/MSO operating structures before SB 351.

Sources:

• AAEM litigation page
• ACEP amicus announcement

2. People ex rel. Allstate Insurance Co. v. Discovery Radiology Physicians, P.C., 94 Cal.App.5th 521 (2023)

Discovery Radiology is a published California appellate decision arising from qui tam / Insurance Frauds Prevention Act and Unfair Competition Law claims. The complaints alleged that physician-owned professional corporations existed in form while a lay person and management entities exercised actual control over radiology operations. The trial court sustained demurrers; the Court of Appeal reversed and held that the operative complaints adequately pled claims.

The decision is important because it treats actual control and undue control as legally meaningful even where physician corporations formally exist. It is still a pleading-stage decision, not a post-trial adjudication that all allegations were true. The Coalition Against Insurance Fraud appeared as amicus supporting the relator/plaintiff side.

Source: law.justia.com

3. Eli Lilly & Co. v. Mochi Health Corp. — 2025–2026 federal litigation

The Mochi Health litigation provides a different control pattern: alleged operational influence over patient-treatment protocols rather than chiefly shareholder succession. In April 2026 the Northern District of California held that Lilly had plausibly alleged a UCL theory based on CPOM where the complaint alleged that an unlicensed corporate actor made decisions affecting treatment practices, including changes in compounded tirzepatide dosing/formulation connected to pharmacy relationships. A September 2026 order on the second amended complaint again treated allegations of continued control over patient-treatment practices as sufficient to keep parts of the UCL conspiracy theory alive.

These are pleading-stage rulings in private competitor litigation, not final findings of liability. They nevertheless show how the CPOM doctrine can reach beyond ownership documents when the alleged control is embedded in clinical protocols, medication decisions or treatment operations.

Sources:

• April 20, 2026 order
• September 8, 2026 order

VIII. AB 3129 and AB 1415: the policy path around SB 351

AB 3129 — the vetoed 2024 precursor

AB 3129 would have required private-equity groups and hedge funds to provide notice to and, in specified circumstances, obtain Attorney General approval for healthcare acquisitions and would have reinforced restrictions on interference with professional judgment. Governor Newsom vetoed the bill on 28 September 2024, stating that the Office of Health Care Affordability was the more appropriate state entity to review healthcare consolidation.

AB 3129 therefore never became law. It belongs in the legislative-history section because it shows the policy concern that later reappeared in SB 351 and AB 1415, but it must not be cited as an operative restriction.

Sources:

• California DOJ sponsorship announcement
• Governor veto message

AB 1415 — transaction transparency around MSOs and control entities

AB 1415 became effective 1 January 2026 and expanded the Office of Health Care Affordability material-change-notice regime. HCAI's implementation guidance says the new “noticing entity” category includes private-equity groups, hedge funds, management services organizations, newly created transaction entities, and entities that own, operate or control a provider. Covered transactions generally require advance notice; the current OHCA portal states that noticing entities use the 90-day advance-notice framework for transactions closing on or after 2 April 2026.

AB 1415 is not a CPOM liability statute. Its importance is transparency: a transaction involving an MSO, a transfer of control, an option, encumbrance or governance change may now generate a public regulatory record that did not exist previously. For the CFMG–Wellpath investigation, the OHCA material-change database should therefore become a permanent monitoring source for future California restructurings, ownership changes, new MSO relationships or transfers involving covered entities.

This sweep did not locate a public OHCA transaction-list entry for “Wellpath,” “California Forensic Medical Group,” or “CFMG” through 25 September 2026. That is a search result, not a conclusion that no filing obligation exists or that no filing has been made under a different entity name.

Sources:

• HCAI AB 1415 FAQ
• OHCA transaction list · OHCA material-change notice system

IX. The California control-indicator matrix

The five-year record supports a much more precise framework than the generic question “does the MSO control the PC?” The investigation should code each issue separately.

X. Fresno Amendment XIII: why the new county record matters more after the California enforcement sweep

The post-22 September Fresno record should now be treated as a live application document for the state control-indicator matrix.

County File 26-0855 assigns Agreement No. 26-459 and Resolution No. 26-329 and lists a Digital Signature Certificate. The Legistar “Final action” field remains blank, so the site should not characterize Board approval as conclusively recorded from that page alone.

The formal recommended action remains an amendment to the County's agreement with California Forensic Medical Group, Incorporated, increasing the cumulative ceiling by $6,104,438 to $400,479,492. But the County's substantive description says Wellpath will provide the CalAIM Justice-Involved reentry services, collaborate with WestCare and managed-care plans, and ensure that “its staff” are credentialed to bill Medi-Cal and trained for accurate billable documentation.

The County also identifies Medusind, Inc. as Wellpath's subcontracted billing vendor, responsible for auditing and quality assurance of claims for jail medical, mental-health and substance-use services. Medusind is to receive 7% of gross revenue collected by the County, with estimated administration fees of approximately $114,323 for the partial FY 2026–27 period, $190,624 in FY 2027–28 and $232,099 in FY 2028–29.

The resulting chain should be reproduced consistently:

County ↔ CFMG as named contractual counterparty → Wellpath as County-described program operator/coordinator → Medusind as Wellpath's subcontracted billing vendor → County as Medi-Cal reimbursement recipient.

This is unusually useful because the same government record uses the two names for different functions. It establishes a layered operating system. It does not establish that Wellpath owns CFMG, that CFMG is a sham professional corporation, that Wellpath exercises physician-reserved judgment, or that “Wellpath's staff” makes Wellpath the legal employer of every worker described.

New questions created by combining Fresno with the 2026 enforcement record

The California enforcement sweep means Fresno Amendment XIII should trigger a new set of document-specific questions:

• Who signs or approves the Medi-Cal provider enrollment and credentialing submissions for physicians and other licensed professionals?
• Who sets the clinical-competency requirements used in credentialing?
• Who negotiates and who approves payer-contract parameters with managed-care plans?
• What exact tasks does Medusind perform before a claim is submitted?
• Can Medusind or Wellpath change a code, modifier, diagnosis linkage or claim without CFMG physician/professional approval?
• Who owns the billing edits and denial-management rules?
• Who has final authority when revenue-cycle guidance conflicts with a treating clinician's documentation?
• Who hires, fires or disciplines the clinicians described by the County as “Wellpath's staff,” and on what authority?
• Which entity is listed as the rendering, billing and organizational provider in Medi-Cal enrollment and claims?
• Does the CalAIM implementation create a new management agreement, subcontract or delegation schedule that changes the preexisting CFMG/Wellpath allocation?

Those are investigation questions, not conclusions.

XI. Wright: keep defense integration separate from corporate control

The September 2026 Estate of Jeremiah Wright filing remains useful but should be coded at a lower evidentiary level than the CPOM/MSO control materials. After the court treated CFMG, Wellpath LLC and Wellpath Management, Inc. separately for bankruptcy/discharge consequences, a later filing identified Medical Defense Law Group attorneys Paul A. Cardinale and Subreen K. Sandhu as counsel for CFMG, Wellpath Management and individual medical defendants together.

That is defense-integration / common-representation evidence. It can support a counsel/claims/insurance/indemnity investigation. It does not prove ownership, alter ego, common employment or professional control. Common counsel may arise from insurance, indemnification, coordinated defense or overlapping facts.

XII. The documents that would resolve the control questions

The enforcement record materially changes the priority of missing CFMG documents. The next investigative pass should seek, in order:

1. Current and historical CFMG stock-transfer, shareholder succession, continuity, nominee, assignable-option, replacement or ownership-preservation agreements.
2. CFMG share ledger, shareholder register, bylaws, board minutes and shareholder consents showing actual owner succession from 2012 through 2026.
3. Complete 2012 MSA, every amendment, the 2019 assignment, post-bankruptcy assumption/continuation documents and any Local Government–California delegation schedules.
4. Termination and post-termination provisions showing what happens to contracts, employees, insurance, EHR access, records, working capital, payer credentials and county relationships if CFMG replaces Wellpath.
5. Any security agreements, UCC filings, intercompany loans, guarantees, credit facilities or liens involving CFMG shares or practice assets.
6. Physician employment and medical-director agreements identifying who hires, evaluates, disciplines, compensates and terminates physicians and who has final clinical-competency authority.
7. Current payroll/W-2/EDD/NLRB records matched worker-by-worker against the County's phrase “Wellpath's staff.”
8. Payer contracting and Medi-Cal enrollment documents identifying who negotiates terms and who approves them on behalf of the professional practice.
9. Medusind master services agreement, statement of work, business-associate agreement, data-access rights, coding-edit rules, denial-management protocols, QA escalation policy and final-claim-approval chain.
10. EHR and patient-record ownership/admin-rights matrix, including who can change templates, content rules, access permissions and retention policy.
11. Medical equipment and supply approval workflows showing professional approval where clinical selection is implicated.
12. Clinical-policy redlines, approval logs and committee minutes showing whether CFMG physicians can reject enterprise clinical policy and whether any demonstrated veto has occurred.
13. Insurance, indemnity, defense and claims-management agreements explaining common representation in Wright and other litigation without conflating that integration with corporate control.
14. Any OHCA/AB 1415 notice, correspondence or internal determination concerning a California Wellpath/CFMG/MSO transaction after 1 January 2026.

XIII. Editorial conclusions for the CFMG–Wellpath investigation

The strongest new conclusion is not that California has already found the CFMG–Wellpath structure unlawful. It has not, on the public record located here.

The stronger and more defensible conclusion is that California's 2021–2026 enforcement record supplies a far more specific set of control tests against which CFMG–Wellpath can now be examined. The state is looking behind nominal physician ownership and asking whether contractual rights, economic dependence, staffing authority, payer control, coding/billing control, records, equipment, treatment protocols and owner-replacement mechanisms give the management side the real last word.

Fresno Amendment XIII is therefore more important after this sweep than it was when treated only as a county contract update. It shows, in one current government record, a professional corporation remaining the formal counterparty while the County describes the MSO as providing and coordinating a new healthcare program and managing credentialing/training and a billing-vendor relationship. That is exactly the kind of functional allocation California's modern CPOM enforcement record tells an investigator to disaggregate.

But the analytical discipline must remain intact. Operational integration is not the same thing as unlawful professional control. A management company can lawfully perform substantial administrative functions. A physician corporation can lawfully use an MSO. The decisive questions are who owns the professional corporation, who controls succession, who can leave whom, who holds reserved powers, who exercises final approval, and what happens when the professional corporation and the management company disagree.

The CFMG investigation now has enough public evidence to frame those questions with precision. The next stage is document acquisition, not rhetorical escalation.

XIV. Status cautions used across this investigation

Use these cautions consistently across the site and dossier:

• Art Center: Attorney General amicus position; appeal pending in the public record reviewed here; not a final appellate holding.
• Carbon Health: DOJ complaint and announced settlement; Attorney General says subject to court approval; OAG-hosted judgment is labeled proposed unless later docket evidence establishes entry.
• Aspen Dental: dentistry analogue; settlement announced as subject to court approval; not medical CPOM precedent against CFMG.
• Medical Board stipulated matters: where the Board says “no admissions,” preserve that language; the disposition is final discipline but not an admission of every charged fact.
• Discovery Radiology: published appellate pleading decision; reversal of demurrer, not a trial finding that all allegations were true.
• Envision/AAEM: important physician-autonomy/CPOM challenge and amicus record, but no final merits ruling declaring the structure unlawful.
• Mochi: private litigation and pleading-stage rulings, not state enforcement or final liability.
• SB 351: effective 1 January 2026; direct new statutory restrictions turn on private-equity/hedge-fund definitions; §1191(g) preserves broader preexisting CPOM law.
• AB 3129: vetoed; never operative law.
• AB 1415: transaction-notice/market-oversight law, not substantive CPOM liability statute.
• Fresno Amendment XIII: Agreement/Resolution numbers and Digital Signature Certificate are in the post-September-22 record, but the Legistar Final action field remains blank; do not claim conclusive approval solely from that page.
• “Wellpath's staff”: evidence of County-described operational responsibility; not dispositive employer identity.
• Wright common counsel: defense-integration evidence only; not ownership, alter ego, common-employer or CPOM proof.

XV. Source register — principal authorities

California Attorney General / DOJ

• Art Center amicus announcement (Apr. 1, 2026)
• Art Center AG amicus brief
• Carbon Health settlement announcement (June 26, 2026)
• Carbon complaint
• Carbon proposed judgment
• Aspen Dental announcement (May 7, 2026)
• DOJ 2023–2024 Biennial Report / Orange Twist
• AB 3129 DOJ announcement

Medical Board of California

• Corporate Practice of Medicine guidance
• Newsletter Volume 164
• Newsletter Volume 165
• Newsletter Volume 166
• Newsletter Volume 167
• Newsletter Volume 168
• Newsletter Volume 169
• Newsletter Volume 170
• Newsletter Volume 171
• Newsletter Volume 172
• Vinh-Linh Ba Nguyen Public Letter

Osteopathic Medical Board

• 2026 new-law policy alert / SB 351
• Apr. 23, 2026 meeting agenda / Attorney General CPOM presentation

Legislation / OHCA

• Health & Safety Code §1191
• AB 3129 veto message
• HCAI AB 1415 FAQ
• OHCA material-change transaction list

Litigation / amici

• People ex rel. Allstate v. Discovery Radiology Physicians, 94 Cal.App.5th 521 (2023)
• AAEM Envision litigation page
• ACEP Envision amicus announcement
• CMA Art Center amicus announcement
• Eli Lilly v. Mochi Health, Apr. 20, 2026 order
• Eli Lilly v. Mochi Health, Sept. 8, 2026 order